Advertisement
Advertisement
NVCR
NovoCure Limited Ordinary Shares
13.21
USDSponsored
+0.06
+0.46%
Nov 02, 15:59 UTC -5
Closed
After-Market
13.20
-0.02
-0.11%
NovoCure Limited Ordinary Shares (NVCR) Earnings
NVCR Earnings Reports
Positive Surprise Ratio
NVCR beat 26 of 44 last estimates.
59%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
NovoCure Limited Ordinary Shares earnings per share and revenue
On Oct 29, 2026, NVCR reported earnings of -0.09 USD per share (EPS) for Q3 26, beating the estimate of -0.24 USD, resulting in a 63.88% surprise. Revenue reached 193.40 million, compared to an expected 185.88 million, with a 4.05% difference. The market reacted with a -7.48% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Vor Biopharma Inc. Common Stock
Report Date
Oct 30, 2026 For Q3 26
Estimate
-$0.83
Actual
-$1.45
Surprise
-74.07%
Emergent Biosolutions, Inc.
Report Date
Nov 02, 2026 For Q3 26
Estimate
-$0.39
Actual
-$0.36
Surprise
+8.61%
AstraZeneca PLC
Report Date
Oct 30, 2026 For Q3 26
Estimate
$2.66
Actual
$2.79
Surprise
+4.56%
Vertex Pharmaceuticals Inc
Report Date
Nov 02, 2026 For Q3 26
Estimate
$4.88
Actual
$4.76
Surprise
-2.51%
Regeneron Pharmaceuticals Inc
Report Date
Oct 30, 2026 For Q3 26
Estimate
$16.56
Actual
$20.07
Surprise
+21.18%
Jazz Pharmaceuticals, Inc.
Report Date
Nov 02, 2026 For Q3 26
Estimate
-$3.93
Actual
-$3.88
Surprise
+1.38%
BioMarin Pharmaceuticals Inc
Report Date
Nov 02, 2026 For Q3 26
Estimate
$0.12
Actual
$0.23
Surprise
+89.77%
Krystal Biotech, Inc. Common Stock
Report Date
Nov 02, 2026 For Q3 26
Estimate
$1.80
Actual
$2.04
Surprise
+13.48%
Axsome Therapeutics, Inc
Report Date
Nov 02, 2026 For Q3 26
Estimate
-$0.59
Actual
-$0.25
Surprise
+58.25%
Travere Therapeutics, Inc. Common Stock
Report Date
Nov 02, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.55
Surprise
-846.64%
FAQ
What were NovoCure Limited Ordinary Shares's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, NovoCure Limited Ordinary Shares reported EPS of -$0.09, beating estimates by 63.88%, and revenue of $193.40M, 4.05% above expectations.
How did the market react to NovoCure Limited Ordinary Shares's Q3 2026 earnings?
The stock price moved down -7.48%, changed from $14.17 before the earnings release to $13.11 the day after.
When is NovoCure Limited Ordinary Shares expected to report next?
The next earning report is scheduled for --.
What are the forecasts for NovoCure Limited Ordinary Shares's next earnings report?
Based on --
analysts, NovoCure Limited Ordinary Shares is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.